Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1
التفاصيل البيبلوغرافية
العنوان:
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1
PURPOSE: Consolidation using high dose chemotherapy with autologous stem cell transplantation (ASCT) is an important component of frontline therapy for children with high-risk neuroblastoma. The optimal preparative regimen is uncertain, though recent data support a role for busulfan/melphalan (BuMel). The Children’s Oncology Group (COG) conducted a trial (ANBL12P1) to assess the tolerability and feasibility of BuMel ASCT following a COG induction. PATIENTS AND METHODS: Patients with newly diagnosed, high-risk neuroblastoma who did not progress during induction therapy and met organ function requirements received intravenous busulfan [every 24 hours × 4 doses based on age and weight] and melphalan (140 mg/m(2) × 1 dose) followed by ASCT. Busulfan doses were adjusted to achieve to an average daily area under the curve (AUC)
